Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Blood progenitor cells will be obtained from a partially matched adult family member (donor).
After processing and filtration using the CliniMACS device, cells will be infused into
participants meeting eligibility criteria.

Prior to transplant, participants will receive a conditioning treatment of rabbit ATG,
cyclophosphamide, fludarabine, thiotepa, melphalan, and rituximab. Mesna will be given to
help prevent side effects of cyclophosphamide. Tacrolimus will be given to help reduce the
risk of GVHD. G-CSF will be given after transplant to help the donor progenitor cells make
white blood cells faster so that the immune system is better able to fight infection.

Blood progenitor cells will be given in two infusions on Day 0 and Day +1. Progenitor cells
then move through the blood stream to the bone marrow space where they should begin to grow.
Participant blood will be monitored for 100 days to assure that the progenitor cells begin to
grow. If the growth is low, additional progenitor cells may be given.

Blood tests will be monitored for up to one year to observe how well the donor cells grow and
their effect on the infection-fighting system.

Inclusion Criteria for Transplant Recipient:

- Age less than or equal to 21 years.

- Any of the following hematologic malignancies that has relapsed or remains refractory
after prior allogeneic HCT (this includes any stage of disease - such as refractory
due to induction failure, refractory in relapse, or in any CR - as long as the
hematologic malignancy remained persistent or returned after a previous allogeneic
HCT):

- ALL, AML, Myeloid Sarcoma, CML, Juvenile myelomonocytic leukemia (JMML),
myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL)

- Has a suitable single haplotype matched (≥ 3 of 6) family member donor.

- Does not have any other active malignancy other than the one for which this transplant
is indicated.

- If prior CNS leukemia, it must be treated and in CNS CR

- Does not have current uncontrolled bacterial, fungal, or viral infection.

- There is no minimum time from the previous transplant, but patients must meet the
following criteria:

- Left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%.

- Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50
ml/min/1.73m2.

- Forced vital capacity (FVC) ≥ 40% of predicted value; or pulse oximetry ≥ 92% on
room air if patient is unable to perform pulmonary function testing.

- Karnofsky or Lansky (age-dependent) performance score ≥ 50 (See Appendix A).

- Bilirubin ≤ 3 times the upper limit of normal for age.

- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the
upper limit of normal for age.

- Not pregnant. If female with child bearing potential, must be confirmed by
negative serum or urine pregnancy test within 14 days prior to enrollment.

- Not breast feeding

Inclusion Criteria for Haploidentical Donor:

- At least single haplotype matched (≥ 3 of 6) family member

- At least 18 years of age.

- HIV negative.

- Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days
prior to enrollment (if female).

- Not breast feeding.

- Regarding donation eligibility, is identified as either:

- Completed the process of donor eligibility determination as outlined in 21 CFR
1271 and agency guidance; OR

- Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of
urgent medical need completed by the principal investigator or physician
sub-investigator per 21 CFR 1271.